ICCG HMFEC Trial
Disease site: Breast Cancer
Treatment Modality: Chemotherapy
Status: In active follow-up
International multicentre randomised study of adjuvant chemotherapy comparing efficacy and toxicity of ‘standard’ dose 5-fluorouracil, epirubicin and cyclophosphamide (FE 50 C) with a ‘higher’ dose 5-flouorouracil, epirubicin and cyclophosphamide (FE 75 C) and evaluating the additional benefit of sequential hormone therapy. 785 premenopausal women with node positive primary breast cancer from 7 countries were randomised to receive 8 cycles of FE 50 C or FE 75 C given at 3 weekly intervals with or without sequential hormone therapy. Depending on hormonal status at the end of chemotherapy patients randomised sequential therapy were prescribed either GnRH agonist for 3 years or tamoxifen for 5 years.
This is an International Collaborative Cancer Group (ICCG) trial (C/9/91).
Marty, Hall, Wils et al, 2002, pp48b. Evaluation of the tolerability of FE 50 C versus FE 75 C in a prospective randomized trial in adjuvant breast cancer patients.